/HEXO
HEXO Stock - HEXO Corp.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.71+2.45%
+$0.02 (+2.45%) • Jun 22
41
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.35
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.78
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HEXO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.70 – $0.72
TARGET (TP)$0.82
STOP LOSS$0.65
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.13
52W High$3.84
52W Low$0.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $191.10M | $123.77M | $80.78M | $47.54M | $4.93M |
| Gross Profit | $-75,672,000 | $48.80M | $-57,975,000 | $26.93M | $6.40M |
| Gross Margin | -39.6% | 39.4% | -71.8% | 56.6% | 129.7% |
| Operating Income | $-1,067,725,000 | $-43,450,000 | $-476,551,000 | $-84,557,000 | $-17,966,556 |
| Net Income | $-1,073,608,000 | $-114,762,000 | $-546,489,000 | $-81,564,000 | $-23,349,799 |
| Net Margin | -561.8% | -92.7% | -676.5% | -171.6% | -473.2% |
| EPS | $-38.68 | $-12.62 | $-63.43 | $-21.47 | $-9.75 |
Company Overview
HEXO Corp., through its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. HEXO Corp. has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HEXOBeat Rate
25%
Last 16 quarters
Avg Surprise
-508.2%
EPS vs Estimate
Beats / Misses
4/12
Last 12 quarters
Latest EPS
$-0.70
Q2 2023
EPS Surprise History
Q4 21
-66.7%
$-2.10vs$-1.26
Q4 21
+10.0%
$-1.26vs$-1.40
Q1 22
-85.7%
$-1.82vs$-0.98
Q2 22
-233.3%
$-1.40vs$-0.42
Q4 22
-25.0%
$-1.40vs$-1.12
Q4 22
-250.0%
$-0.98vs$-0.28
Q1 23
+13.6%
$-0.19vs$-0.22
Q2 23
-6900.0%
$-0.70vs$-0.01
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | Jun 12, 2024 | — | — | — | — |
Q1 2024 | Mar 14, 2024 | — | — | — | — |
Q4 2023 | Dec 13, 2023 | — | — | — | — |
Q4 2023 | Oct 30, 2023 | $-0.04 | — | — | — |
Q2 2023 | Jun 14, 2023 | $-0.01 | $-0.70 | -6900.0% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.22 | $-0.19 | +13.6% | ✓ BEAT |
Q4 2022 | Dec 15, 2022 | $-0.28 | $-0.98 | -250.0% | ✗ MISS |
Q4 2022 | Oct 31, 2022 | $-1.12 | $-1.40 | -25.0% | ✗ MISS |
Q2 2022 | Jun 14, 2022 | $-0.42 | $-1.40 | -233.3% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.98 | $-1.82 | -85.7% | ✗ MISS |
Q4 2021 | Dec 14, 2021 | $-1.40 | $-1.26 | +10.0% | ✓ BEAT |
Q4 2021 | Oct 29, 2021 | $-1.26 | $-2.10 | -66.7% | ✗ MISS |
Q2 2021 | Jun 14, 2021 | $-0.84 | $-1.68 | -100.0% | ✗ MISS |
Q1 2021 | Mar 18, 2021 | $-0.42 | $-1.82 | -333.3% | ✗ MISS |
Q4 2020 | Dec 14, 2020 | $-1.12 | $-0.56 | +50.0% | ✓ BEAT |
Q4 2020 | Oct 29, 2020 | $-1.68 | $-2.80 | -66.7% | ✗ MISS |
Q2 2020 | Jun 11, 2020 | $-2.80 | $-2.24 | +20.0% | ✓ BEAT |
Q1 2020 | Mar 30, 2020 | $-3.36 | $-4.48 | -33.3% | ✗ MISS |
Q4 2019 | Dec 16, 2019 | $-5.04 | $-5.60 | -11.1% | ✗ MISS |
Q4 2019 | Oct 28, 2019 | $-2.80 | $-6.16 | -120.0% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about HEXO
What is HEXO's current stock price?
HEXO Corp. (HEXO) is currently trading at $0.71 per share. The stock has moved +2.45% today.
What is the analyst price target for HEXO?
No analyst price targets are currently available for this stock.
What sector is HEXO Corp. in?
HEXO Corp. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is HEXO's market cap?
HEXO Corp. has a market capitalization of $0.03 billion, making it a small-cap company.
Does HEXO pay dividends?
No, HEXO Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLK
Allakos Inc.
$0.33
Mkt Cap: $0.0B
ANGN
Angion Biomedica Corp.
$1.00
Mkt Cap: $0.0B
CYTH
Cyclo Therapeutics, Inc.
$0.72
Mkt Cap: $0.0B
ISO
IsoPlexis Corporation
$0.76
Mkt Cap: $0.0B
LIANY
LianBio
$0.11
Mkt Cap: $0.0B
MRNS
Marinus Pharmaceuticals, Inc.
$0.55
Mkt Cap: $0.0B
RENB
Lunai Bioworks Inc.
$1.42
Mkt Cap: $0.0B
SDCCQ
SmileDirectClub, Inc.
$0.00
Mkt Cap: $0.0B
SHCR
Sharecare, Inc.
$1.43
Mkt Cap: $0.5B
SNCE
Science 37 Holdings, Inc.
$5.75
Mkt Cap: $0.0B
Explore stocks similar to HEXO for comparison